Northern Trust’s Immunovant IMVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$16.7M Buy
672,774
+106,626
+19% +$2.76M ﹤0.01% 1785
2025
Q4
$14.4M Buy
566,148
+10,233
+2% +$228K ﹤0.01% 1887
2025
Q3
$8.96M Sell
555,915
-19,468
-3% -$315K ﹤0.01% 2177
2025
Q2
$9.21M Buy
575,383
+38,761
+7% +$586K ﹤0.01% 2123
2025
Q1
$9.17M Buy
536,622
+9,255
+2% +$194K ﹤0.01% 2087
2024
Q4
$13.1M Buy
527,367
+20,377
+4% +$578K ﹤0.01% 1967
2024
Q3
$14.5M Buy
506,990
+43,269
+9% +$1.28M ﹤0.01% 1832
2024
Q2
$12.2M Sell
463,721
-14,986
-3% -$426K ﹤0.01% 1878
2024
Q1
$15.5M Sell
478,707
-15,987
-3% -$583K ﹤0.01% 1771
2023
Q4
$20.8M Buy
494,694
+15,326
+3% +$564K ﹤0.01% 1590
2023
Q3
$18.4M Sell
479,368
-13,492
-3% -$305K ﹤0.01% 1602
2023
Q2
$9.35M Buy
492,860
+81,813
+20% +$1.53M ﹤0.01% 2113
2023
Q1
$6.38M Sell
411,047
-6,896
-2% -$120K ﹤0.01% 2308
2022
Q4
$7.42M Buy
417,943
+68,068
+19% +$857K ﹤0.01% 2215
2022
Q3
$1.95M Sell
349,875
-7,366
-2% -$36K ﹤0.01% 3024
2022
Q2
$1.39M Sell
357,241
-11,245
-3% -$48.6K ﹤0.01% 3235
2022
Q1
$2.03M Sell
368,486
-20,910
-5% -$130K ﹤0.01% 3094
2021
Q4
$3.32M Sell
389,396
-1,649
-0.4% -$13.6K ﹤0.01% 2953
2021
Q3
$3.4M Sell
391,045
-26,265
-6% -$237K ﹤0.01% 2985
2021
Q2
$4.41M Sell
417,310
-32,341
-7% -$452K ﹤0.01% 2917
2021
Q1
$7.21M Sell
449,651
-17,187
-4% -$453K ﹤0.01% 2513
2020
Q4
$21.6M Buy
466,838
+37,807
+9% +$1.75M ﹤0.01% 1736
2020
Q3
$15.1M Buy
429,031
+155,699
+57% +$4.68M ﹤0.01% 1835
2020
Q2
$6.66M Buy
273,332
+251,701
+1,164% +$5.39M ﹤0.01% 2350
2020
Q1
$337K Sell
21,631
-1,943
-8% -$29.2K ﹤0.01% 3547
2019
Q4
$374K Buy
+23,574
New +$264K ﹤0.01% 3628

Other funds holding IMVT

Northern Trust's IMVT Position: Q1 2026 in Review

Northern Trust increased its Immunovant (IMVT) stake by 19% in Q1 2026, buying an estimated $2.76M and bringing the position to 672,774 shares worth $16.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1785.

Northern Trust first reported a position in IMVT in Q4 2019 and has held it in 26 quarters since. The position peaked at $21.6M in Q4 2020. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Northern Trust held 672,774 shares of Immunovant worth $16.7M as of Q1 2026.
  • Northern Trust bought 106,626 Immunovant shares in Q1 2026, an estimated $2.76M.
  • Immunovant made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #1785 holding.
  • Northern Trust first reported a position in Immunovant in Q4 2019 and has held it in 26 quarters since.
  • Northern Trust's Immunovant position peaked at $21.6M in Q4 2020.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.